Neurotoxicity after Treatment with Muromonab-CD3

Publisher Website
Google Scholar
Abstract
Large doses of antibody directed against the CD3 antigen of lymphocytes are immunosuppressive — an effect that has been successfully exploited in the treatment of human renal-allograft rejection.1 Recently, studies in mice have demonstrated immunologic enhancement and tumor regression after the administration of low-dose antimurine CD32 (and Gallinger S, et al.: unpublished data). We have initiated a Phase I study of antihuman CD3 (muromonab-CD3) in patients with refractory solid tumors. The treatment consists of a single intravenous injection of muromonab-CD3 every 14 days. Functional and phenotypic analysis of peripheral-blood mononuclear cells and quantitation of circulating lymphokines are performed in association with treatment, and tumor response is evaluated after every third treatment.